獸醫疼痛管理市場機會、成長動力、產業趨勢分析及 2025-2034 年預測

2024 年全球獸醫疼痛管理市場價值為 22 億美元，預計 2025 年至 2034 年期間的複合年成長率將達到 6.5%。市場成長的動力包括寵物擁有量的增加、動物保健意識的提高以及寵物人性化趨勢的日益增強。關節炎、癌症和關節痛等慢性疾病的流行增加了對有效疼痛管理解決方案的需求。此外，獸醫外科手術的數量持續增加，進一步增加了對疼痛管理藥物和設備的需求。由於動物產品消費量的增加，牲畜健康也成為關注的重點。為了維持生產力，畜牧生產者正在採用疼痛管理解決方案來確保動物的健康。獸醫醫院的擴張、疼痛管理藥物的線上供應量的增加以及遠距醫療作用的日益增強進一步促進了市場擴張。

獸醫疼痛管理包括用於緩解動物急性和慢性疼痛的藥物和設備。 2021 年市值為 19 億美元，2022 年為 20 億美元，2023 年為 21 億美元。就產品而言，藥品部分在 2024 年佔總市佔率的 85.4%。它進一步按類型、給藥途徑和配銷通路分類。按類型分類，該部分包括非類固醇抗發炎藥、鴉片類藥物、麻醉劑和α-2激動劑。

給藥途徑分為口服、注射和外用，配銷通路包括獸醫院藥房、零售藥局和網路藥局。藥物在市場上佔據主導地位，是因為它們易於獲得，並且能夠有效控制疼痛和發炎。非類固醇抗發炎藥和鴉片類藥物因其療效明確而被廣泛使用。由於骨關節炎、關節疾病和癌症等慢性疾病的發生率不斷上升，對疼痛管理藥物的需求持續上升。藥物配方的進步提高了療效，減少了給藥頻率，增強了適口性，使其得到了更廣泛的接受。

獸醫疼痛管理市場也按應用細分，其中關節痛在 2024 年佔據最大佔有率，為 53.7%。該細分市場在 2024 年的價值為 12 億美元，預計到 2034 年將達到 21 億美元，複合年成長率為 6.3%。關節疼痛包括骨關節炎和肌肉骨骼疾病等疾病。抗發炎藥物和改善病情的骨關節炎藥物等先進治療方法的出現促進了這一領域的擴張。

根據動物類型，市場分為伴侶動物和牲畜動物。伴侶動物細分市場在 2024 年引領市場，預計在預測期內的複合年成長率為 6.4%。此類別包括狗、貓、馬和其他伴侶動物。隨著寵物的飼養數量不斷增加以及其壽命的延長，對獸醫疼痛管理解決方案的需求也隨之增加。隨著寵物年齡的成長，它們更容易患上慢性病，因此需要採取有效的緩解疼痛的措施。寵物保險的成長和獸醫費用的增加進一步支持了這一領域的擴張。

2024 年，北美佔據全球獸醫疼痛管理市場的主導地位，佔有 43.9% 的佔有率。發達的獸醫保健基礎設施、較高的寵物收養率以及​​大量的牲畜數量增強了該地區的市場實力。美國市場價值在 2021 年為 7.855 億美元，2022 年成長至 8.175 億美元，2023 年成長至 8.536 億美元，進一步鞏固了其作為市場成長主要貢獻者的地位。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

• 產業生態系統分析
• 產業衝擊力
  • 成長動力
    • 寵物擁有量和動物保健支出不斷增加
    • 動物慢性病盛行率上升
    • 已開發國家對寵物保險的認知有所提高
    • 獸醫外科手術激增
    • 獸醫學的進步
  • 產業陷阱與挑戰
    • 與止痛藥相關的副作用
    • 專業技能人才短缺
• 成長潛力分析
• 監管格局
• 波特的分析
• PESTEL分析

第4章：競爭格局

• 介紹
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 策略儀表板

第5章：市場估計與預測：按產品，2021 年至 2034 年

• 主要趨勢
• 藥物
  • 按類型
    • 非類固醇抗發炎藥
    • 鴉片類藥物
    • 麻醉藥
    • α-2激動劑
    • 其他類型
  • 依給藥途徑
    • 口服
    • 腸外
    • 外用
  • 按配銷通路
    • 獸醫院藥房
    • 零售藥局
    • 網路藥局
• 裝置
  • 按類型
    • 雷射治療儀
    • 電磁治療儀
  • 按最終用途
    • 獸醫醫院和診所
    • 學術和研究機構

第6章：市場估計與預測：按應用，2021 年至 2034 年

• 主要趨勢
• 關節疼痛
  • 骨關節炎
  • 肌肉骨骼
• 癌症痛
• 術後疼痛
• 其他應用

第7章：市場估計與預測：依動物類型，2021 年至 2034 年

• 主要趨勢
• 伴侶動物
  • 狗
  • 貓
  • 馬匹
  • 其他伴侶動物
• 家畜
  • 牛
  • 豬
  • 其他牲畜

第8章：市場估計與預測：按地區，2021 年至 2034 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 荷蘭
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第9章：公司簡介

• Alivira Animal Health
• Boehringer Ingelheim
• Ceva Santé Animale
• Chanelle Pharma
• Dechra Pharmaceuticals
• Elanco Animal Health
• K-Laser USA
• Merck
• Multi Radiance Medical
• Norbrook
• Vetoquinol
• Zoetis

The Global Veterinary Pain Management Market was valued at USD 2.2 billion in 2024 and is projected to expand at a 6.5% CAGR from 2025 to 2034. The market growth is driven by increasing pet ownership, rising awareness of animal healthcare, and the growing trend of pet humanization. The prevalence of chronic diseases such as arthritis, cancer, and joint pain has heightened the demand for effective pain management solutions. Additionally, the number of veterinary surgical procedures continues to rise, further boosting the need for pain management drugs and devices. Livestock health has also become a critical focus due to the rising consumption of animal-based products. To maintain productivity, livestock producers are adopting pain management solutions to ensure animal well-being. The expansion of veterinary hospitals, increasing online availability of pain management drugs, and the growing role of telemedicine have further contributed to market expansion.

Veterinary pain management includes drugs and devices used to relieve acute and chronic pain in animals. In 2021, the market was valued at USD 1.9 billion, followed by USD 2 billion in 2022 and USD 2.1 billion in 2023. In terms of products, the drugs segment accounted for 85.4% of the total market share in 2024. It is further categorized by type, route of administration, and distribution channel. By type, the segment includes NSAIDs, opioids, anesthetics, and alpha-2 agonists.

The route of administration is divided into oral, parenteral, and topical, while the distribution channel includes veterinary hospital pharmacies, retail pharmacies, and online pharmacies. The dominance of drugs in the market is attributed to their easy availability and effectiveness in managing pain and inflammation. NSAIDs and opioids are widely used due to their well-established efficacy. The demand for pain management drugs continues to rise due to the increasing prevalence of chronic diseases such as osteoarthritis, joint disorders, and cancer. Advancements in drug formulations have improved efficacy, reduced dosage frequency, and enhanced palatability, making them more widely accepted.

The veterinary pain management market is also segmented by application, with joint pain holding the largest share of 53.7% in 2024. This segment was valued at USD 1.2 billion in 2024 and is projected to reach USD 2.1 billion by 2034 at a CAGR of 6.3%. Joint pain includes conditions such as osteoarthritis and musculoskeletal disorders. The availability of advanced treatments, including anti-inflammatory drugs and disease-modifying osteoarthritis drugs, has contributed to the expansion of this segment.

By animal type, the market is classified into companion animals and livestock animals. The companion animals segment led the market in 2024 and is expected to grow at a 6.4% CAGR during the forecast period. This category includes dogs, cats, horses, and other companion animals. The increasing adoption of pets and their longer lifespan have heightened the demand for veterinary pain management solutions. As pets age, they become more susceptible to chronic conditions, necessitating effective pain relief measures. The growth of pet insurance and rising veterinary expenditures have further supported the expansion of this segment.

North America dominated the global veterinary pain management market in 2024, holding a 43.9% share. The well-developed veterinary healthcare infrastructure, high pet adoption rates, and substantial livestock population contribute to the region's market strength. The U.S. market, which was valued at USD 785.5 million in 2021, grew to USD 817.5 million in 2022 and USD 853.6 million in 2023, further solidifying its position as the leading contributor to market growth.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising pet ownership and animal healthcare spending
    • 3.2.1.2 Rising prevalence of chronic diseases in animals
    • 3.2.1.3 Increased awareness about pet insurance in developed countries
    • 3.2.1.4 Surge in veterinary surgical procedures
    • 3.2.1.5 Advancements in veterinary medicine
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Side effects associated with pain medications
    • 3.2.2.2 Shortage of skilled professionals
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Drugs
  • 5.2.1 By type
    • 5.2.1.1 NSAIDs
    • 5.2.1.2 Opioids
    • 5.2.1.3 Anesthetics
    • 5.2.1.4 Alpha-2 agonists
    • 5.2.1.5 Other types
  • 5.2.2 By Route of Administration
    • 5.2.2.1 Oral
    • 5.2.2.2 Parenteral
    • 5.2.2.3 Topical
  • 5.2.3 By Distribution channel
    • 5.2.3.1 Veterinary hospital pharmacies
    • 5.2.3.2 Retail pharmacies
    • 5.2.3.3 Online pharmacies
• 5.3 Devices
  • 5.3.1 By Type
    • 5.3.1.1 Laser therapy devices
    • 5.3.1.2 Electromagnetic therapy devices
  • 5.3.2 By End Use
    • 5.3.2.1 Veterinary hospitals & clinics
    • 5.3.2.2 Academic and research institutes

Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Joint pain
  • 6.2.1 Osteoarthritis
  • 6.2.2 Musculoskeletal
• 6.3 Cancer pain
• 6.4 Postoperative pain
• 6.5 Other applications

Chapter 7 Market Estimates and Forecast, By Animal Type, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Companion animals
  • 7.2.1 Dogs
  • 7.2.2 Cats
  • 7.2.3 Horses
  • 7.2.4 Other companion animals
• 7.3 Livestock animals
  • 7.3.1 Cattle
  • 7.3.2 Swine
  • 7.3.3 Other livestock animals

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Alivira Animal Health
• 9.2 Boehringer Ingelheim
• 9.3 Ceva Santé Animale
• 9.4 Chanelle Pharma
• 9.5 Dechra Pharmaceuticals
• 9.6 Elanco Animal Health
• 9.7 K-Laser USA
• 9.8 Merck
• 9.9 Multi Radiance Medical
• 9.10 Norbrook
• 9.11 Vetoquinol
• 9.12 Zoetis